Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: A systematic literature review of real‐world evidence
AD Raval, KD Kistler, Y Tang, Y Murata… - Transplant Infectious …, 2021 - Wiley Online Library
Kidney transplant recipients (KTRs) have increased risk for cytomegalovirus (CMV)
infection/disease given the necessity of drug‐induced immunosuppression. A …
infection/disease given the necessity of drug‐induced immunosuppression. A …
Epidemiology, management, and burden of cytomegalovirus in solid organ transplant recipients in selected countries outside of Europe and North America: A …
HT Silva Junior, Y Tokat, J Cai, I Singh… - Transplant Infectious …, 2023 - Wiley Online Library
Background Cytomegalovirus (CMV) is a frequent infectious complication following solid
organ transplantation (SOT). Considering significant differences in healthcare systems, a …
organ transplantation (SOT). Considering significant differences in healthcare systems, a …
Risk factors for failure of primary (val) ganciclovir prophylaxis against cytomegalovirus infection and disease in solid organ transplant recipients
MP Khurana, IP Lodding, A Mocroft… - Open Forum …, 2019 - academic.oup.com
Background Rates and risk factors for cytomegalovirus (CMV) prophylaxis breakthrough and
discontinuation were investigated, given uncertainty regarding optimal dosing for CMV …
discontinuation were investigated, given uncertainty regarding optimal dosing for CMV …
Low-Dose vs Standard-Dose Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplantation: A Single-Center Retrospective Analysis
K Farkas, M Varga, I Dinnyes, L Rem, G Telkes… - Transplantation …, 2024 - Elsevier
Background Prophylactic administration of valganciclovir (VG) is an accepted method for the
prevention of cytomegalovirus (CMV) infection after kidney transplantation (KTx). The …
prevention of cytomegalovirus (CMV) infection after kidney transplantation (KTx). The …
Low‐dose valganciclovir prohylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti‐thymocyte globulin
M Eriksson, JJ Jokinen, S Söderlund… - Transplant Infectious …, 2018 - Wiley Online Library
Background Cytomegalovirus (CMV) remains an important pathogen in solid organ
transplant patients. Objective We executed a hybrid prophylactic and pre‐emptive …
transplant patients. Objective We executed a hybrid prophylactic and pre‐emptive …
Evaluation of Alternate-Day Valganciclovir Prophylaxis for Cytomegalovirus Disease Prevention in Moderate Risk Renal Transplant Patients: A Retrospective …
P Bhuwania, I Veerappan… - Indian Journal of …, 2021 - journals.lww.com
Background: Despite valganciclovir (VGCV) being the recommended agent for
Cytomegalovirus (CMV) disease prevention, its optimal dose that maintains parity between …
Cytomegalovirus (CMV) disease prevention, its optimal dose that maintains parity between …
Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study
K Korneffel, G Mitro, K Buschor, M Rees, J Ortiz - Transplant Immunology, 2019 - Elsevier
Abstract Objectives Alemtuzumab (Ale) is a recombinant monoclonal antibody which binds
to CD52 causing profound lymphodepletion, thus allowing its use in renal transplantation …
to CD52 causing profound lymphodepletion, thus allowing its use in renal transplantation …
Efficacy and safety of low-dose valganciclovir prophylaxis among renal transplant recipients
İ Ergun - Cukurova Medical Journal, 2020 - dergipark.org.tr
Purpose: Cytomegalovirus (CMV) infection is one of the most common infections observed
following kidney transplantations. Transplantations between cytomegalovirus …
following kidney transplantations. Transplantations between cytomegalovirus …
Current characteristics and outcomes of Cytomegalovirus Reactivation in kidney transplant seropositive recipients in the era of prophylaxis treatment. Lesson from …
Despite the use of antiviral prophylaxis, the active cytomegalovirus (CMV) replication is still
occurred in the seropositive kidney recipients. The aim of this study was to assess the …
occurred in the seropositive kidney recipients. The aim of this study was to assess the …
[PDF][PDF] Current characteristics and outcomes of Cytomegalovirus Reactivation in kidney 2 transplant seropositive recipients in the era of prophylaxis treatment. Lesson …
A Ibrahimi, M Seffar, H Kabbaj - scholar.archive.org
Despite the use of antiviral prophylaxis, the active cytomegalovirus (CMV) replication is still
20 occurred in the seropositive kidney recipients. The aim of this study was to assess the 21 …
20 occurred in the seropositive kidney recipients. The aim of this study was to assess the 21 …